Implementing Disruptive Technologies With Confidence in Cell Therapy
Panelists from Lonza, Takeda and Vor Biopharma share their insights on how to best introduce disruptive technologies into cell therapy manufacturing processes.
During our recent Phacilitate Advanced Therapies Week breakfast briefing, cell therapy manufacturing executives Nicholas Ostrout from Lonza, Fabio Fachin from Takeda and Matthew Li from Vor Biopharma shared their insights on disruptive technologies in cell therapy. Invetech’s David Hodl, Head of Business Development, moderated the discussion.
Introducing new technologies into a cell therapy manufacturing process presents multiple potential benefits, risks and cost. Understanding the critical decisions points that companies face as they scale their production and move towards commercialization can help manufacturers introduce disruptive technologies appropriately.
The panel discussed:
- Evaluation criteria for bringing in new manufacturing technology
- The factors involved in aligning platform and process development
- Bringing disruptive technologies into the process in the context of clinical timelines
- When is it beneficial to use something in PD (process development) before it is GMP (good manufacturing practice) ready?
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.